Table 3.
Medication use by JIA ILAR categories and ACR treatment groups. Counts for non-biologic DMARD, biologic DMARD, and intra-articular GC include ever use.
| Classification | Non-Biologic DMARD | Biologic DMARD | Intra-Articular GC | Any Systemic GC | Current Systemic GC | Current Daily NSAID |
|---|---|---|---|---|---|---|
| Oligoarthritis | 387 (53%) | 143 (20%) | 467 (65%) | 118 (16%) | 14 (2%) | 370 (51%) |
| Extended Oligoarthritis | 200 (89%) | 104 (46%) | 157 (70%) | 61 (27%) | 6 (3%) | 108 (48%) |
| RF− Polyarthritis | 666 (83%) | 431 (54%) | 313 (39%) | 340 (42%) | 79 (10%) | 400 (50%) |
| RF+ Polyarthritis | 181 (91%) | 136 (68%) | 73 (37%) | 125 (63%) | 43 (22%) | 118 (59%) |
| ERA | 181 (63%) | 132 (46%) | 77 (27%) | 103 (36%) | 21 (7%) | 162 (57%) |
| Psoriatic | 142 (84%) | 99 (58%) | 60 (35%) | 56 (33%) | 10 (6%) | 72 (42%) |
| Systemic | 202 (82%) | 160 (65%) | 82 (33%) | 204 (83%) | 62 (25%) | 114 (46%) |
| Undifferentiated | 40 (65%) | 23 (37%) | 21 (34%) | 22 (35%) | 3 (5%) | 36 (58%) |
| History of ≤ 4 active joints | 594 (57%) | 270 (26%) | 573 (55%) | 223 (21%) | 35 (3%) | 536 (51%) |
| History of ≥ 5 active joints | 1,219 (84%) | 812 (56%) | 600 (42%) | 609 (42%) | 144 (10%) | 738 (51%) |
DMARD = methotrexate, leflunomide, or sulfasalazine; GC = glucocorticoid; NSAID = non-steroidal anti-inflammatory drug; RF =rheumatoid factor; ERA = enthesitis-related arthritis